Troy Wilson, Kura Oncology CEO
#ASH22: Kura’s menin inhibitor heads to PhII in subset of acute myeloid leukemia with mixed data
NEW ORLEANS — Kura Oncology said the FDA has agreed on a Phase II dose for a registrational trial of its lead drug, and at a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
